APM Key Statistics, Chart & Performance
The current stock price of APM is 1.06 USD. In the past month the price decreased by -27.14%. In the past year, price decreased by -26.62%.
APM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.45 | 391.59B | ||
| AMGN | AMGEN INC | 14.97 | 176.24B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 150.67B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.9 | 118.48B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.31B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782.39 | 52.71B | ||
| INSM | INSMED INC | N/A | 37.05B | ||
| NTRA | NATERA INC | N/A | 33.76B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.1 | 21.71B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About APM
Company Profile
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
Company Info
APTORUM GROUP LTD-CLASS A
17 Hanover Square
London W1S 1BN GB
CEO: Ian Huen
Employees: 1
Phone: 85239537700
APTORUM GROUP LTD-CLASS A / APM FAQ
What does APM do?
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
What is the stock price of APTORUM GROUP LTD-CLASS A today?
The current stock price of APM is 1.06 USD. The price increased by 3.92% in the last trading session.
Does APTORUM GROUP LTD-CLASS A pay dividends?
APM does not pay a dividend.
How is the ChartMill rating for APTORUM GROUP LTD-CLASS A?
APM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is APM stock listed?
APM stock is listed on the Nasdaq exchange.
Can you provide the market cap for APTORUM GROUP LTD-CLASS A?
APTORUM GROUP LTD-CLASS A (APM) has a market capitalization of 8.63M USD. This makes APM a Nano Cap stock.
What is the ownership structure of APTORUM GROUP LTD-CLASS A (APM)?
You can find the ownership structure of APTORUM GROUP LTD-CLASS A (APM) on the Ownership tab.
APM Technical Analysis
APM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to APM. APM may be in some trouble as it scores bad on both profitability and health.
APM Financial Highlights
Over the last trailing twelve months APM reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 13.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.46% | ||
| ROE | -20.19% | ||
| Debt/Equity | 0 |
APM Forecast & Estimates
For the next year, analysts expect an EPS growth of 8528.57% and a revenue growth -78.44% for APM